Comorbidities associated with sleep apnoea

Obstructive sleep apnoea (OSA) and central sleep apnoea (CSA) go hand in hand with health conditions that affect the respiratory, nervous, cardiovascular and endocrine systems.

Why is it important to manage SDB in cardiac patients?

If obstructive sleep apnoea is not effectively managed, it can have serious consequences on your patient’s cardiovascular health on the long term. Watch this video to learn more.

Sleep apnoea and hypertension

People with sleep-disordered breathing (SDB) have an increased risk of developing hypertension, independent of other relevant risk factors.1-5 This risk is related to SDB severity: the more severe the SDB, the greater the risk of developing hypertension.

During healthy sleep, blood pressure decreases, but SDB patients instead tend to experience:

  • elevated blood pressure during sleep;
  • prolonged cardiovascular stress, which can lead to increased blood pressure also occurring during the day.

SDB is present in more than 30% of patients with hypertension,and in around 80% of patients with drug resistant hypertension.5 For this group of patients in particular, treatment with positive airway pressure therapy may be especially important.7

Sleep apnoea and heart failure 

Up to 50% of heart failure patients experience moderate to severe sleep-disordered breathing (SDB),8 in the form of central sleep apnoea (CSA), Cheyne-Stokes respiration (CSR), obstructive sleep apnoea (OSA) or a combination thereof.9

 

What is Cheyne-Stokes respiration?

Cheyne-Stokes respiration (CSR) occurs when periods of hyperventilation and hypoventilation (in a waxing/waning breathing pattern) alternate with periods of central hypopnoea/apnoea. CSR is a common form of SDB in patients with severe left ventricular dysfunction.10

 

How does CSR affect heart failure?

It’s thought that SDB and CSR accelerate the progression of heart failure by causing:

  • Repetitive hypoxia;
  • Increased afterload;
  • Increased sympathetic activity;11
  • Oscillations in heart rate and blood pressure.

Fragmented sleep resulting from CSR also causes fatigue and daytime sleepiness, which impacts quality of life.

A large MediCare study on newly diagnosed heart failure patients has shown that those with SDB have a worse prognosis compared to those without.12 Nocturnal CSA/CSR in itself is associated with increased mortality13 in congestive heart failure patients.
Learn more about the treatment options for patients with CSR.

Sleep apnoea and stroke

The majority of patients who have experienced a stroke and transient ischemic attack also have SDB,14  which is sometimes undiagnosed. As stroke patients with SDB also have worse functional outcomes15, you should consider screening for SDB16 when investigating the stroke.

Stroke has the potential to cause SDB, by either affecting:

  • central mechanisms resulting in central sleep apnoea;
  • muscle tone resulting in obstructive sleep apnoea.

 

Can sleep apnoea predispose people to strokes?

People with sleep apnoea may be predisposed to stroke through a number of symptoms they experience. In particular:

  • Repetitive drops in nocturnal blood oxygen levels caused by sleep apnoea can result in intermittent hypoxia which has been shown to be associated with systemic inflammation.17
  • Sleep fragmentation from sleep apnoea results in hypersympathetic activity.18

 

What is the impact of sleep apnoea on post-stroke rehabilitation?

Patients with both sleep apnoea and stroke usually show poor compliance with post-stroke rehabilitation programs. This is mainly due to the combination of:

  • the deficits caused by the stroke;
  • the symptoms of SDB (such as excessive daytime sleepiness, fatigue, and impaired cognitive functioning).

 

Recognising sleep apnoea in stroke survivors is often challenging because the symptoms associated with sleep apnoea are often attributed to stroke. A complete sleep history from family members can help you determine whether sleep apnoea was present prior to the stroke or developed after the stroke.

Sleep apnoea and type 2 diabetes

Sleep apnoea is common among patients with type 2 diabetes.19 It is independently associated with insulin resistance, glucose intolerance and metabolic syndrome,20-22 and when untreated, can lead to poor overall treatment outcomes.

However, despite the number of type 2 diabetes patients with SDB, it largely goes undiagnosed.

 

Screen your patients for type 2 diabetes and sleep apnoea

As a result of accumulated research, the International Diabetes Federation recognises the association between type 2 diabetes and sleep apnoea, and recommends routinely screening OSA patients for type 2 diabetes, and screening type 2 diabetes patients displaying sleep apnoea symptoms for OSA.

And because patients with sleep apnoea and patients with diabetes share similar comorbidities, screening both ways is recommended: check for sleep apnoea in diabetes patients, and check for diabetes in patients with sleep apnoea.23

Sleep apnoea and COPD

Obstructive Sleep Apnoea and Chronic Obstructive Pulmonary Disease (COPD) are two diseases that often coexist within a patient.

COPD is a condition that describes the progressive deterioration of the respiratory system by pulmonary airway obstruction, emphysema and decreased airflow. COPD also refers to lung disorders such as chronic bronchitis, and in some cases, chronic asthma.

 

SDB prevalence in COPD patients

According to the American Thoracic Society, patients with Chronic Obstructive Pulmonary Disease (COPD) have a higher prevalence of sleep disorders than the general population, with close to 50% of patients reporting significant disturbance in sleep quality.

Co-existence of both COPD and OSA occurs in 1% of adults.24

 

COPD risks in SDB patients

COPD and OSA are often coined as overlap syndrome. Both COPD and OSA are independent risk factors for the following:

  • Arrhythmia;
  • High blood pressure;
  • Heart attack;
  • Stroke;
  • Other cardiovascular disease.

Studies have shown that patients with untreated overlap syndrome have a higher mortality rate1. We at ResMed strive to impact comorbidity and improve quality of life. We offer a range of treatment options to alleviate the symptoms of COPD.

Although scientists continue to research the risks created by, and associated with, sleep apnoea, patients’ sleep-disordered breathing often goes untreated. Learn how to get your patients screened for sleep apnoea and how to treat them to diminish the risk of other chronic diseases.

Referenser:

    1. Peppard PE et al. N Engl J Med. 2000
    2. Lavie P et al. BMJ. 2000 
    3. Nieto FJ, Young TB et al. JAMA. 2000
  1. Bixler EO, Vgontzas AN at al. Arch Intern Med. 2000 
  2. Marin JM et al. JAMA. 2012 
  3. Logan AG, Perlikowski SM et al. J Hypertens. 2001 
  4. Montesi et al. Journal of Clinical Sleep Medicine. 2012 
  5. Bitter T. et al, EJHF, 2009 
  6. Oldenburg O et al. Circ J 2012 
  7. Lanfranchi PA et al. Circulation. 2003 
  8. Garcia-Touchard A et al. Chest. 2008 
  9. Javaheri S et al. AJRCCM. 2011 
  10. Javaheri S et al. J Am Col Cardiol. 2007 
  11. Johnson KG, et al. J Clin Sleep Med. 2010 
  12. Martínez-García MA, et al. Am J Respir Crit Care Med. 2009 
  13. Wessendorf TE, et al. J Neurol. 2000 
  14. Drager LF, et al. Chest. 2011 
  15. Jelic S, et al. Trends Cardiovasc Med. 2008 
  16. Einhorn et al. Endocr Pract. 2007 
  17. Aronsohn et al. Am J Respir Crit Care Med. 2010 
  18. Punjabi et al. Am J Respir Crit Care Med. 2002 
  19. Coughlin et al. Eur Heart J. 2004 
  20. International Diabetes Federation. The IDF consensus statement on sleep apnoea and type 2 diabetes. Brussels, Belgium: International Diabetes Federation; 2008 
  21. Ruth Lee, Walter T. McNicholas. Obstructive Sleep Apnea in Chronic Obstructive Pulmonary Disease Patients. Curr Opin Pulm Med. 2011;17(2):79-83.